Effect of pentoxifylline on developmental changes in neutrophil cell surface mobility and membrane fluidity.
Polymorphonuclear leukocytes (PMNs) from human neonates respond less efficiently to chemotactic factor stimulation than do PMNs from adults. The biologic mechanisms underlying this developmental process are poorly understood. In previous studies, we have found that pentoxifylline, an agent report to enhance membrane deformability, increased the chemotactic response of neonatal PMNs. In the present studies, we have examined the effect of pentoxifylline on cell surface mobility and membrane fluidity by assessing fluorescent concanavalin A (Con A) capping and fluorescent polarization (FP). Baseline Con A capping was lower in the PMNs of neonates when compared to PMNs from adult controls. Colchicine, which increases capping by disrupting microtubules, exaggerated the differences between the adult and neonatal PMNs. Following exposure of neonatal PMNs to pentoxifylline, colchicine enhanced Con A capping to levels equivalent to those of colchicine-treated PMNs from adults. Employing a fluorescence polarization (FP) assay, we found the fluid state of the membrane of PMNs from neonates was significantly less than that of adult controls. Pentoxifylline alone significantly increased the fluidity of the cell membranes of neonatal PMNs while decreasing elevated basal levels of F-actin in the cell. These data suggest an intrinsic cytoskeletal difference in the PMNs of neonates that may be responsive to pharmacologic manipulation.
Newton
J A
JA
Department of Pediatrics, University of Utah School of Medicine, Salt Lake City 84132.
Ashwood
E R
ER
Yang
K D
KD
Augustine
N H
NH
Hill
H R
HR
D000199:Actins / Q000097:blood; D000328:Adult; D000440:Butanols / Q000494:pharmacology; D002465:Cell Movement / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D008560:Membrane Fluidity / Q000187:drug effects*; D009504:Neutrophils / Q000502:physiology* / Q000648:ultrastructure; D010431:Pentoxifylline / Q000494:pharmacology*; D011956:Receptors, Cell Surface / Q000502:physiology; D011952:Receptors, Concanavalin A / Q000502:physiology; D013805:Theobromine / Q000031:analogs & derivatives*
D000199:Actins; D000440:Butanols; D011956:Receptors, Cell Surface; D011952:Receptors, Concanavalin A; D013805:Theobromine; D010431:Pentoxifylline